Richard Serbin was Chief FDA Counsel at Revlon Corporation, and Chief FDA for Johnson & Johnson Corporation. He was also Vice President of Corporate Development at Johnson & Johnson and sat on the Board of Directors of sixteen of its domestic and international operating companies including its companies involved in biotechnology, dermatology, female health, veterinary medicine, photodynamic therapy, wound care, artificial heart valves, surgical and consumer products.
Richard is a global strategy advisors and entrepreneur with credentials in both pharmacy and law, complemented by more than 40 years of service as an FDA Regulatory Attorney, and Patent Attorney in the healthcare industry. Mr. Serbin is an expert in licensing healthcare products and technologies in both the domestic and international markets.
He serves as Managing Director of Platform Health Ventures, a healthcare strategic and tactical consulting group. He served as President of Bradley Pharmaceuticals; Chief Operating Officer of the Gorlin Companies; Co-founder of Radius Scientific (sold to Pearson Plc); President of Advanced Therapeutics Communications; President of Professional Post Graduate Service; Vice President of Physician World Communications; President of Medication Service; Co-founder and President of Bio-Imaging Technologies (Sold to Covance); Co-Founder of Optigenex; President of Oxford Market Research; and, Executive Vice President of Kimberly Quality Care. He has been a member of private and public Boards of Directors including: Co Diagnostics (Chairman of the Compensation Committee; Mountainside Hospital; Bio-Imaging Technologies (licensed technology from NASA LANDSAT program); DemeRx (Chairman of the Board); Gilrose (Chairman of the Board; and Seaweed Bio-Technology.